GSK announces positive results from phase III trial of cancer drug competitor to Genmab's Darzalex
In the phase III study, the anticancer agent has been tested in combination with two other agents.
British pharmaceutical company GSK announced on Monday that its cancer drug, belantamab mafodotin, has reached the primary endpoint in a preliminary phase III study testing the drug as a second-line treatment for relapsed or refractory multiple myeloma.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
